VHCP Management II as of Sept. 30, 2016
Portfolio Holdings for VHCP Management II
VHCP Management II holds 24 positions in its portfolio as reported in the September 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Avexis | 21.9 | $43M | 1.0M | 41.21 | |
| BioCryst Pharmaceuticals (BCRX) | 12.9 | $25M | 5.7M | 4.41 | |
| Edge Therapeutics | 10.3 | $20M | 1.9M | 10.41 | |
| Dbv Technologies (DBVTF) | 10.0 | $19M | 374k | 52.04 | |
| Ascendis Pharma A S (ASND) | 7.4 | $15M | 721k | 20.10 | |
| Cytomx Therapeutics (CTMX) | 4.7 | $9.1M | 578k | 15.68 | |
| Audentes Therapeutics | 3.7 | $7.3M | 459k | 15.84 | |
| Heron Therapeutics (HRTX) | 3.6 | $7.0M | 406k | 17.23 | |
| Colucid Pharmaceuticals | 3.1 | $6.1M | 159k | 38.15 | |
| Axovant Sciences | 3.1 | $6.0M | 430k | 14.00 | |
| Regenxbio Inc equity us cm (RGNX) | 2.4 | $4.7M | 333k | 14.01 | |
| Alcobra | 1.9 | $3.8M | 1.5M | 2.47 | |
| Beigene | 1.9 | $3.7M | 119k | 30.81 | |
| Coherus Biosciences (CHRS) | 1.8 | $3.5M | 130k | 26.78 | |
| D Stemline Therapeutics | 1.8 | $3.4M | 316k | 10.83 | |
| Achillion Pharmaceuticals | 1.8 | $3.4M | 420k | 8.10 | |
| Akari Therapeutics | 1.6 | $3.1M | 370k | 8.51 | |
| ARCA biopharma | 1.6 | $3.1M | 1.1M | 2.83 | |
| Ocera Therapeutics | 1.5 | $2.9M | 1.1M | 2.64 | |
| Aeglea Biotherapeutics | 1.1 | $2.2M | 350k | 6.38 | |
| Lipocine | 1.0 | $1.9M | 420k | 4.46 | |
| Adverum Biotechnologies | 0.6 | $1.2M | 280k | 4.11 | |
| Zafgen | 0.2 | $468k | 142k | 3.31 | |
| Pronai Therapeutics | 0.1 | $238k | 131k | 1.82 |
